Durable tumor responses and significant levels of disease control rates have been described in more than 20 advanced/ metastatic cancer types with B7-family immune checkpoint-targeted anti-CTLA-4, anti-PD-1, and anti-PD-L1 monoclonal antibodies. These results and the recent approvals of ipilimumab, pembrolizumab, nivolumab and atezolizumab are currently revolutionizing the way we envision the future of cancer care. However these clinical benefits are not observed in all cancer types and in every patient. Therefore, our clinical challenge is to identify therapeutic strategies which could overcome the primary and secondary resistances to these novel cancer immunotherapies. Pattern recognition receptors (PRRs) are other critical costimulatory molecules of immune cells, notably myeloid cells (macrophages and dendritic cells). They were initially described as sensors for 'danger signals' released by pathogens (e.g. viral DNA and bacterial proteins). We know now that PRRs can also be recruited and activated upon recognition of endogenous stress signals such as molecules released upon self-cell death (e.g. ATP and HMGB1). Natural endo/exogenous or synthetic PRRs agonists have notably the ability to activate phagocytosis and antigen presentation by myeloid cells residing in the tumor micro-environment. In pre-clinical models, these PRRs agonists have also been shown to overcome the resistance to T-cell targeted immune checkpoints anti-CTLA-4 and anti-PD-1/PD-L1. This manuscript reviews the current knowledge on this major family of immune receptors and the molecules targeting them which are currently in clinical development.
Introduction
At the end of the 19th century, an American surgeon named Dr William Coley showed that inoperable cancers could be treated by repeated injections of live or inactivated Streptococcus pyogenes and Serratia marcescens bacteria [1] . More than 120 years later, Coley is considered to be one of the pioneers of cancer immunotherapy. Indeed, based on our current understanding of tumor immunology, his controversial strategy of injecting pathogen extracts into tumors to stimulate the anti-tumor immunity has become of great interest.
It is now known that within the cancer microenvironment reside immunosuppressive lymphoid and myeloid cells such as regulatory T cells (T reg ), tumor-associated macrophages (TAMs), tolerogenic plasmacytoid or myeloid dendritic cells (pDCs and mDCs), and myeloid-derived suppressor cells (MDSCs) [1, 2] .
Together with the tumor cells and immunosuppressive cytokines (e.g. IL-10, TGF-b), these cells hamper the generation of an efficient anti-tumor immune response and therefore favor tumor growth and metastasis. Novel cancer immunotherapy strategies are now focusing on the depletion, blockade or reprogramming of these tolerogenic immune effectors. The aim of this review is to gather the scientific rationale for the use of pattern recognition receptor (PRR) agonists in cancer therapy, and discuss routes of administration which might potentiate their clinical benefits in combination with existing immunotherapy strategies.
The family of pattern recognition receptors
In 2011, the Nobel Prize of medicine rewarded J. Hoffman, and B. Beutler (and acknowledged the contribution of C. Janeway and R. Medzhitov) for their discovery of PRRs and the description of their role in activating cells from the innate and adaptive immune systems. PRRs are germline encoded receptors which play a central role in the immune response against pathogens but also in immune healing upon self-injuries. PRRs consist of five families including Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), C-type lectin receptors (CLRs) and DNA sensors. They detect pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), flagellin, lipoproteins, but also structural proteins, RNA and DNA from bacteria, virus, fungi and parasites [3] . They can also recognize endogenous damage-associated molecular patterns (DAMPs) that are released upon cellular stress, apoptosis or necrosis, such as chromatin-associated protein highmobility group box1 (HMGB1), heat shock proteins (HSPs) and proteins from the extracellular matrix that are generated following tissue injury like hyaluronan [4] . DAMPs/PAMPs recognition by PRRs leads to transient pro-inflammatory gene expression, and immune cell activation. However, inappropriate activation of PRRs has been linked to chronic inflammation and autoimmune diseases notably TLR9 and DNA sensors in systemic lupus erythematosus [5] or psoriasis [6] .
Targeting Toll-like receptors for cancer immunotherapy
Toll-like receptors (TLRs) are trans-membrane proteins which function as homo or hetero-dimers. They can be either expressed at the cell surface (TLR 1, 2, 5, and 6) or within the endosomes (TLR 3, 7, 8, 9 and 10) or both (TLR4 can be expressed both at the surface or internalized within the endosomes) [7] . They are conserved among species except for TLR 11, 12 and 13 which are not found in humans. Following recognition of their cognate PAMPs or DAMPs, TLRs become active and trigger signaling pathways via their intracellular TIR domain and the recruitment of specific adaptor proteins such as MYD88, TRIF, TIRAP or TRAM ( Figure 1 ). MYD88 is an adaptor protein for all TLRs except TLR3 that signals via TRIF [8] . The downstream signaling leads separately to the translocation of NF-jB and IRF3/7 transcription factors into the nucleus, and the regulation of the expression of genes involved in several cellular processes such as survival, proliferation, and inflammatory cytokine and type-I IFN secretion [9] .
Until recently, it was believed that TLR expression was restricted to immune cells (Figure 2 ) or in cells involved in the first line of defense (such as epithelial intestinal cells or endothelial cells). Indeed the activation of TLRs on antigen presenting cells (APCs) enhances antigen presentation, leads to the expression of inflammatory cytokines and up regulates the expression of adhesion and co-stimulatory molecules at the cell surface [10] . In addition, TLRs play multiple roles in the activation and differentiation of B cells in combination with other signaling pathway triggered by the B-cell receptor (BCR) stimulation. Notably, TLR signaling has been shown to regulate the antibody responses including germinal center formation and autoantibody production in an autoimmune disease model [11] . TLRs can also function as co-stimulatory receptors for T cells to enhance their proliferation, survival and cytokine production. Notably, it has been shown that TLR2 engagement on CD8(þ) memory T cells can directly contribute to the maintenance of their diversity in the organism and induce their proliferation and IFN gamma secretion both in vivo and in vitro [12] . TLRs can also modify directly or indirectly the immunosuppressive functions of CD4 þ CD25þ Treg cells, as it has been shown that TLR2 ligands (Pam3Cys) can significantly increase Treg cell number but resulting in a transient loss of the suppressive Treg phenotype in vitro [13] . It has been also observed that engagement of TLR4 by LPS (TLR4 agonist) on T reg (CD4 þ CD25 þ FOXP3þ T-cells or Tregs) can enhance their proliferation, their survival and more importantly their immunosuppressive capacities [14] .
More recently, it has been proposed that TLR could also be expressed by tumor cells [15] . Interestingly, DNA-damage and cell stress inducing agents such as doxorubicin chemotherapy, can induce a p53-dependent upregulation of TLR expression [16] . The stimulation of such tumor-associated TLR by synthetic agonists can either promote or inhibit tumor progression. For instance, in vitro exposure of TLR-expressing tumor cell lines derived from neuroblastoma [17] , lymphoma [18] , prostate adenocarcinoma [19] and breast carcinoma [20] to their cognate TLR agonists inhibited cell growth and induced apoptosis. In other instances, TLR agonists paradoxically enhanced tumor progression as it has been shown that T reg can become activated after being exposed to LPS [14] . Other effects have been linked to the sustained endogenous stimulation of TLRs and the subsequent continuous secretion of pro-inflammatory cytokines which promote chronic inflammation, angiogenesis and metastasis [21] . In breast cancer cell lines, stimulation with LPS strongly up-regulated TLR4 expression but also matrix metalloproteases (MMP-2 and -9) and VEGF at mRNA and protein levels, suggesting a direct role of TLRs in tumor aggressiveness [22] . These results were confirmed in vivo in a nude mouse breast carcinoma model, where stimulation of TLR4 by LPS promoted tumorigenesis and metastasis in the liver [22] . TLR expression measured by tissue microarray and immunohistochemistry on 73 biopsies, has been also found in Stage I-II oral squamous cell carcinoma [23] . In this type of cancer, a high TLR-2, 4 and 9 expression was correlated with higher tumor invasiveness, whereas high TLR5 expression correlated with a lower tumor grade. In another study, Chatterjee and Cremer have observed that the stimulation of TLR7 in immunodeficient and immunocompetent mice transplanted with TLR7 positive NSCLC tumor cell lines has a protumoral effect and induces resistance to chemotherapy [24] . In addition, patients with high TLR7 expression correlate to poor prognosis outcome [24] . In acute myeloide leukemia (AML), it has been shown that TLR8 activation promotes AML differentiation and cell growth inhibition [25] . It was also demonstrated that the TLR7/8 agonist R848 impairs the growth of human AML cells in immunodeficient mice [25] . Therefore a single TLR stimulation can lead to either anti-or pro-tumoral signaling depending on the targeted TLR and the type of cancer. However these contradictory results on the role of TLRs could also be the consequence of the experimental settings. For instance, TLR gene expression data do not inform on the effects of therapeutic stimulation of TLRs. In addition, in vitro TLR stimulation on cancer cell line or xenograft models might not lead to the same results in vivo on tumors with an immunocompetent microenvironment. This potential dual role of TLR agonists has been recently reviewed by Pradere et al. [26] .
Multiple TLR agonists are currently in clinical development (Table 1) . Intratumoral injections of a TLR-9 agonist, the CpGrich oligonucleotide PF-3512676, has already shown significant activity in both injected and non-injected lesions of B-and T-cell lymphomas when used concomitantly with low-dose (2Â2 Gy) local irradiation. Out of 15 patients with low-grade B-cell lymphoma, 27% developed an objective response (1 CR þ 3 PR) and 2 other patients showed stable but continually regressing disease (disease control rate of 40%) [27] . Similar results have been also reported in patients with T-cell lymphoma [28] .
As shown in Table 1 , several compounds, mainly represented by imiquimod and imiquimod derivatives, target TLR 7 and 8. TLR7 in pDC is functionally associated with the production of IFN-a-and IFN-regulated cytokines, similar to the role of TLR9. TLR8 functions in monocytes and myeloid DC and is involved in the production of proinflammatory cytokines such as TNF-a [29] . Intratumoral administration of the TLR7/8 agonist 3M-052/MEDI9197 in a mouse melanoma model generated antitumor response and has been shown to potentiate the effects of anti-CTLA4 and anti-PDL1 therapies [30] . Several studies have shown that synthetic dsRNA induce apoptosis in tumor cells in a TLR3-dependent manner [20, 31] . So activation of TLR3 by specific ligands may induce apoptosis of tumor cells and activate the immune system at the same time. In a randomized clinical trial including 194 breast cancer patients, adjuvant treatment with poly(A:U) dsRNA was associated with a significant decrease in the risk of metastatic relapse in TLR-3-positive but not in TLR3-negative breast cancers [32] . Their expression remains at low levels but can increase after viral infection and exposure to type-I IFN in a large variety of other cell types, including cancer cells [33] . Recent studies have highlighted an anti-tumor activity of RLR activation [34] . RIG-I stimulation can inhibit leukemia cell proliferation via STAT-1 expression and transcription of several genes implicated in type-I and II IFN induction [35] . Interestingly, it has been shown recently that blocking TGF-b by siRNA can simultanously stimulate RIG-I and induce high levels of type-I IFN and CXCL10 in the serum and tumor tissue which subsequently activates systemic immune cells and tumor cell apoptosis in vivo in murine pancreatic tumors [36] . In melanoma cells the activation of RIG-I and MDA-5 can induce a type-I IFN-independent apoptosis [37] and autophagy [38] .
The interaction of MDA-5 and RIG-I with their ligands triggers a signaling pathway through the binding to the mitochondrial membrane adaptor protein mitochondrial antiviral signaling protein (MAVS) which eventually results in the nuclear translocation of the transcription factors IRF3 and NF-jB and type-I IFN production [39] . Meanwhile, their interaction triggers another signaling pathway independent of the tumor suppressor p53 resulting in mitochondrial apoptosis through caspase-9 and Apaf-1 as well as activation of the proapoptotic BCL-2 family member NOXA [37] . In addition, recent data has shown that the stimulation of RIG-I in human ovarian cancer cells by short double stranded RNA with uncapped 5 0 -triphosphate (direct RIG-I agonist) [40] or stimulation of MDA-5 with poly I:C [41] leads to HLA-class-I upregulation, proinflammatory cytokines secretion, tumor cell apoptosis and phagocytosis by monocytes and dendritic cells. Moreover the cytoplasmic transfection of breast cancer cells with poly I:C has been shown to trigger a caspase dependent apoptosis and a cell growth arrest via MDA-5 stimulation [42] . A recent study reported that polyinosinepolycytidylic acid (poly-IC), a synthetic dsRNA which is known to act as a TLR3 and RLR agonist, can stimulate apoptosis in pancreatic cancer cells while sparing normal pancreatic epithelial cells. The mechanism of action of this effect involved the inhibition of survival, XIAP expression and the activation of an immune response by inducing MDA-5 and RIG-1. Interestingly, the in vivo administration of poly-IC can inhibit tumor growth in subcutaneous and orthotopic pancreatic tumor models [43] . Altogether this data illustrates the anti-tumor potential of RLRs activation through the induction of apoptosis in tumor cells and the stimulation of anti-tumor immunity. Some RIG-I agonists should reach soon the clinic in early phase trials.
Targeting NOD-like receptors for cancer immunotherapy NOD-like receptors (NLRS) are another family of proinflammatory cytosolic PRRs. They are divided into four subfamilies, each with a suffix to denote their unique type of N-terminal domain: NLRA-A in reference to their acidic transactivating domain, NLRB-B in reference to their Baculovirus Inhibitor of apoptosis protein Repeat (BIR) domain, NLRC-C in reference to their Caspase Activation and Recruitment Domain (CARD), and NLRP-P in reference to their Pyrin Domain (PYD) [44] . Some NLRs including NOD1, NOD2 apoptosis inhibitory protein (NAIP) and NLRC4 can detect conserved bacterial molecular signatures such as c-D-glutamyl-meso-diaminopilemic acid (iE-DAP) or muramyl dipeptide (MDP) that are produced during synthesis or degradation of bacteria cell wall peptidoglycan within the host cytosol. Other members of the NLR family can detect danger signals such as DAMPs. NLR stimulation leads to NF-jB activation and pro-inflammatory cytokines secretion, leading to inflammation and enhanced immune response. However, it has been shown recently that NLRP12 can suppress TLR1/2  TLR5   TLR5  TLR5  TLR5   TLR8   TLR2/6  TLR1/2   TLR2/6   TLR4  TLR4  TLR1/2  TLR10   TLR4   TLR10  TLR10  TLR1/2   TLR1/2  TLR10   TLR7 TLR9   TLR1/2   TLR9   TLR8  TLR2/ 
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Continued colon inflammation and tumorigenesis through negative regulation of non-canonical NF-jB signaling [45] . Most NLRs play an important role in a multiprotein complex called the inflammasome, that activates caspase-1 and leads to the secretion of proinflammatory cytokines IL-1b and IL-18 via proteolytic cleavage of pro-peptides [46] . However, NLRP10 seems to be an exception as it is the only NLR lacking the common ligand-binding leucine-rich-repeat domain. Moreover, it does not function through an inflammasome to regulate caspase-1 activity nor does it regulate other inflammasomes. Interestingly, NLRP10 has been recently described to play an important role in the migration of DCs and the initiation of adaptive immune responses [47] . Other reports have shown that ATP released from apoptotic cells can be sensed by DCs through NLRP3 inflammasome activation via the generation of Reactive Oxygen Species (ROS). This NLRP3 activation can lead to the secretion of IL-1b by DCs, and can induce an anti-tumor immunity by effective recruitment of CD8 T-cells and can promote tumor clearance by phagocytes [48] . Mifamurtide (liposomal muramyl tripeptide), a NOD-2 agonist, is currently approved in the E.U. for the treatment of non-metastatic osteosarcoma in conjunction with chemotherapy, and this molecule showed immunomodulatory properties via the activation of monocytes and macrophages [49] .
Targeting cytosolic DNA sensors for cancer immunotherapy
Stetson and Medzhitov reported in 2006 the induction of type-I IFN by cytosolic DNA in cells lacking TLR9, the only previously known sensor of foreign DNA [50] . Since then, it has been shown that cytoplasmic aberrant DNA can activate three different TLR9-independent pathways. First, DNA can be recognized by cytoplasmic sensors such as DNA-dependent Activator of IFNregulatory factors (DAI) and lead to the production of type-I IFNs via IRF3 nuclear translocation [51] . Second, foreign DNA can be retro-transcribed by RNA polymerase-III and become a ligand for RNA sensor like RIG-I [52] . Third, several groups have identified AIM2 (Absent In Melanoma 2) as a cytosolic DNA sensor whose activation promotes the assembly of an inflammasome leading to the cleavage of caspase-1, the expression of IL-1b and IL-18. This pathway leads to the induction of a unique caspase-1-dependent cell death called pyroptosis [53] . Recent data has revealed that AIM2 stimulation in colorectal cancer cells can lead to the upregulation of interferon stimulated genes such as the MHC-II molecule HLA-DR [54] . This novel function seemed independent of caspase-1 and resulted in cell cycle arrest but conferred an invasive phenotype to colorectal cancer cells [55] . AIM2 contradictory role was also recently linked to the development of benign prostate hyperplasia and prostate cancer by sustaining chronic inflammation [56] . In another study it was shown that electroporation of a DAIencoding plasmid in vivo in mice can augment the transcription of genes encoding proinflammatory cytokines, type-I IFN and costimulatory molecules [57] . Moreover, DAI used as an adjuvant with a DNA vaccine (encoding for a tumor antigen) led to an anti-tumor cytotoxic T-cell (CTL) response and inducedmemory CTLs [57] . Recently a new endoplasmic reticulum transmembrane protein playing a crucial role in the recognition of cytosolic DNA has been identified and named stimulator of IFN genes (STING). STING is also known as MITA, ERIS and MPYS and is encoded by the TMEM173 gene in humans. Cytosolic DNA binds to cGAMP synthase (cGAS) and catalyses cyclic GMP-AMP (cGAMP) synthesis from ATP and GTP. cGMP then binds and activates STING [58] and induces a conformational change which leads to activation of transcriptional factors IRF3 and NFjB through the kinase TBK1 and IKK [59] . STING has been shown to play an important role in the innate immune response against cancer. It was recently demonstrated that in the tumor microenvironment, tumor cells DNA detected by APCs is correlated with activation of STING pathway that leads to IFN-b production and spontaneous T cell response against tumors [60] . The rationale of targeting STING in the tumor microenvironment is to activate cross-priming of tumor-specific antigens to CD8þ T cells and induce the production of chemokines to enhance the trafficking of effector T cells [61] . Some studies have shown that the administration of different doses of STING ligand, cyclic di-GMP, can reduce the number of metastasis and tumor size in a metastatic breast cancer mouse model. Interestingly, low dose of cyclic di-GMP enhances the production of IL-12 by MDSC and improve T-cell responses but high dose of cyclic di-GMP leads to activation of caspase-3 in tumor cells that can directly kills them [62] . STING agonists are currently in clinical development. For instance the molecule ADU-S100 (Aduro Biotech/Novartis), has been reported as stimulating the different variants of human STING receptors. ADU-S100 is currently evaluated in a phase I clinical trial using intratumoral (IT) administration. Encouraging preclinical results were obtained with the lead molecules, which induced, after IT administration, tumor regressions in different syngeneic mouse models, with immune protection after re-challenge with the same tumor [61] . No significant local or systemic toxicity was reported in those preclinical mouse models.
Targeting C-type lectins receptors for cancer immunotherapy C-type lectins receptors (CLRS) are large trans-membrane receptors characterized by a carbohydrate recognition domain (CRD) which binds in a calcium dependent manner to glycans present on the surface of microorganisms [63] . They are principally implicated in the recognition (and clearance) of fungi and facilitate the antigen internalization and processing by DCs. Based on their molecular structure, CLRs can be separated in two groups of transmembrane CLRs and secreted CLRs. Among transmembrane CLRs, a first subgroup contains several CRDs or CRD-like domains and includes receptors such as DEC-205 (CD205) or the macrophage mannose receptor (MMR). These CLRs can play a role in antigen uptake by APC, resulting in the presentation of peptides by MHC class I and II molecules [64] . A second subgroup presents a single CRD domain and includes molecules such as Dectin-1, Dectin-2, macrophage-inducible C-type lectin (Mincle), DC-specific ICAM3-grabbing non-integrin (DC-SIGN), and DC NK lectin group receptor-1 (DNGR-1 or Clec9A). These receptors play notably a critical role in fungal recognition and the subsequent activation of innate immune responses [65] . A second group of CLRs is composed by soluble CLRs like for instance the Mannose-binding lectin (MBL), an oligomeric protein that binds to carbohydrate patterns on pathogen surfaces [66] . CLR engagement by their ligands triggers specific signaling pathways (Figure 1 ). These pathways lead to the expression of different cytokines directly or by modulating the TLR signaling pathways, and result in T cell polarization [63] . It was recently shown that oral administration or intraperitoneal injection of MD-fraction (a highly purified soluble b-Glucan extract from the oriental mushroom Grifola frondosa) in tumor bearing mice lead to the induction of systemic anti-tumor immunity [67] . MD-fraction was taken up by antigen presenting cells and induced their maturation via Dectin-1 pathway, leading to an infiltration of activated T cells into the tumors and a decrease of immunosuppressive cells such as Tregs and MDSCs. More recently, new data showed an essential role of CLRs in the induction of inflammation after necrotic cell death. Indeed, Mincle and Clec9A have been shown to recognize DAMPs released upon necrosis but not apoptosis [68, 69] . Genetic variants of C-type lectin genes were associated with colorectal cancer susceptibility [70] . Imprime PGG, a beta 1,3/1,6-glucan PAMP derived from yeast is currently in clinical development [71] . At ASCO 2015, the company reported the results of a 2:1 randomized Phase II trial testing Imprime PGG w/o carboplatin þ paclitaxel þ bevacizumab in 92 patients with non-squamous NSCLC. The combination arm with Imprime PGG showed rapid and durable objective responses in 60% of the patients versus 43% in the control arm [72] .
PRR agonists to overcome immune checkpoint blockade resistance
The current revival of cancer vaccines is supported by the hypothesis that the pre-existing anti-tumor immunity might be insufficient in anti-PD-1/PD-L1 refractory patients and that tumor-antigen exposure might trigger a better priming of antitumor T-cells. Thanks to their immuno-stimulatory properties, notably in terms of activation of antigen presenting cells, PRR agonists are now being extensively used as cancer vaccines adjuvants (Table 1) . Alternatively, the administration of PRR agonists could be done directly into a tumor lesion where all the relevant tumor antigens are present in order to prime or boost the antitumor T-cell immunity (Figure 3) . Interestingly, the rationale for such strategy has been shown in both murine models and humans. First, it has been shown that intratumoral PRR agonist injections can trigger a more effective anti-tumor immune response than upon distant or systemic administrations [18, 73] . Indeed, intratumoral injections of PRR agonists can induce a local inflammation with chemokines which can recruit infiltrative myeloid cells in the tumor microenvironment. Moreover, PRR agonists can activate these myeloid cells and enhance their ability to efficiently present tumor antigens to T-cells and activate the anti-tumor immune response. PRR agonists can also have an intrinsic direct anti-tumor activity on the injected tumors [18, 74, 75] and generate regression of non-injected, distant tumor sites [61] . The proof of concept of the benefits of local PRR agonist delivery has been recently done in humans with lymphoma [27, 28] . Injections of CpG, a TLR9 agonist, into a single tumor site together with a local low-dose (2Â2 Gy) irradiation were able to trigger a systemic anti-tumor immune response and generate objective tumor responses at distant, non-injected, sites. Concerning the route of administration, an IT injection of PRRs agonists not only achieve a maximal local therapeutic effect with compounds often characterized by poor pharmacokinetic properties, but also allows to limit the side effects of a systemic immune activation. Interestingly, this so called 'in situ immunization' strategy just follows the practice that Dr William Coley developed more than a century ago.
PRR agonists can also potentiate the systemic activity of conventional therapies when used in combination with chemotherapy [18] , tumor-targeted antibodies [76] , or tumor-targeted tyrosine kinase inhibitors [77] . Most of all, some PRR agonists have been shown to overcome the resistance to immune checkpoint targeted antibodies therapy. In a murine model of B-cell lymphoma that is resistant to anti-CTLA4, anti-OX40, and anti-GITR therapy, Houot and Levy have demonstrated that intratumoral injections of CpG, a TLR9 agonist, could trigger a systemic anti-tumor immune response able to eradicate distant, noninjected, tumor lesions [75] . In two other syngeneic mouse tumor models of melanoma and colorectal cancer that are resistant to anti-PD-1 therapy, Fu et al. [78] have shown that a STING agonist-based cancer vaccine could trigger a systemic anti-tumor immune response able to eradicate both the injected tumor site and the distant, untreated, tumor sites.
Pathogens as natural sources of PRR agonists
Beyond synthetic molecules, entire pathogens with multiple potential PRR agonistic function via their constitutive proteins and nucleic acids can be used for cancer therapy. Beyond its approved use for local bladder cancer, cutaneous and intratumoral BCG therapy has been extensively used to treat cancers in the past with significant clinical activity, including responses in non-injected lesions (see [79] for review). More recently, in a randomized phase 2 study, another mycobacteria (Mycobacterium obuense) has shown activity in metastatic pancreatic cancer when injected sub-cutaneously in combination with gemcitabine. Besides bacteria, viruses can also be used to stimulate PRRs and infect/kill cancer cells in an immunogenic manner. The whole field of oncolytic viruses is currently in active development. Indeed, Talimogene laherparepvec (aka T-Vec), a GM-CSF expressing, herpes virus (HSV-1) derived, oncolytic virus, has been recently approved for the treatment of metastatic melanoma following the positive results of a randomized phase III trial [80] . Intratumoral T-VEC injection resulted in a decrease in size by at least 50% in 64% of injected tumors, 34% of non-injected non-visceral tumors and 15% of non-injected visceral tumors [81] . Pexa-Vec, a GM-CSF expressing vaccinia virus-derived oncolytic virus is currently in phase 3 in hepatocarcinoma following promising activity in both injected and non-injected tumor lesions in phase I and II trials [82, 83] . Interestingly, early data of intratumoral oncolytic virus therapy seem to show that it can synergize with anti-CTLA-4 and anti-PD-1 therapy with objective response rates >50% and including responses in non-injected lesions [84, 85] .
Conclusion
Due to their immune stimulatory properties, PRR agonists can contribute to the induction of systemic and long lasting adaptive immunity against tumors. Moreover, PRR agonists can also directly induce an immunogenic cell death, a particular type of apoptosis that trigger immune responses specific for dead cell-associated antigens [86] . Cancer vaccines or intratumoral administrations with PRR agonists can induce potent anti-tumor immune responses. However, therapies with PRR agonists might not be sufficient to overcome tumor antigen tolerance within the tumor microenvironment and its draining lymph nodes. Combination of therapies based on PRR agonists with immune checkpoint targeted antibodies such as anti-CTLA-4 or anti-PD-1 could address this issue and overcome the resistance to immune checkpoint blockade monotherapy.
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